AbbVie (NYSE: ABBV) announced on May 14, 2025 that EMRELIS™ (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy.
The Florida Society of Pathologists (FSP) mourns the loss of Dr. Morton Levitt, a devoted member, esteemed pathologist, and visionary leader whose passion and advocacy profoundly shaped our society.